Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs
Bullboard Posts
User Avatar Image
(1)
•••
Post by ReportTraderon Jun 26, 2007 8:46am
369 Views
Post# 12998128

halo on its way (ni 43-101 an so on)

halo on its way (ni 43-101 an so on)the new ressource estimate for the sherridon project is there by july/august 07 (NI 43-101) !!! 11 mio. tonnes (copper, zinc, gold, silber) worth more than 1 billion CA$, market cap now 20 mio. CA$ !! just count this worth with 5 percent and the stock has to move 300% up by now! there are only 35 mio. shares out of HLO! !! and there are still 2 gold projects (red lake and duport) 45,000 m drilling in total on sherridon. gold projects: duport - partner is goldcorp, drilling is going on here, too. halo already has an NI 43-101 estimate red lake - very large deposit, not sure whats going on here right now. Greetz from Germany Report_Trader (Zocker_Freak)
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities